A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
Completed
- Conditions
- Renal Disease
- Registration Number
- NCT05967806
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2575
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of patients with UACR>700mg/g or UPCR >1000mg/g and eGFR 20-90 mL/min/1.73 m2 approximately 10 months Summary statistics
- Secondary Outcome Measures
Name Time Method Number and sort of antihypertensive drugs among patients in different geographical regions approximately 10 months Use of medications
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are implicated in proteinuria progression in CKD patients identified in NCT05967806?
How do current treatment patterns for proteinuric CKD in NCT05967806 compare to standard-of-care therapies like ACE inhibitors or SGLT2 inhibitors?
Which biomarkers are being evaluated in NCT05967806 to predict response to future renal disease interventions?
What adverse event profiles are observed in proteinuria-managed CKD cohorts across AstraZeneca's observational studies?
How does NCT05967806's patient characterization align with emerging drug targets for diabetic nephropathy or glomerular disease?
Trial Locations
- Locations (1)
Research Site
🇻🇳Ho Chi Minh City, Vietnam